Evidence map›Paper›PMID 24357797›Full record

ArticleBritish journal of cancer2014

IGFBP7 is associated with poor prognosis in oesophageal adenocarcinoma and is regulated by promoter DNA methylation.

E Smith, A R Ruszkiewicz, G G Jamieson, P A Drew

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Plasma Insulin-like Growth Factor-Binding Protein-7 Is Positively Associated with Age, Obesity, Mortality, and Cancer in Postmenopausal Women.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

E SmithSolid Cancer Regulation Research Group, Discipline of Surgery, Basil Hetzel Institute for Translational Health Research, The University of Adelaide, The Queen Elizabeth Hospital, 28 Woodville Road, Woodville South 5011, South Australia, Australia.
A R RuszkiewiczSA Pathology, Frome Road, Adelaide 5000, South Australia, Australia.
G G JamiesonDiscipline of Surgery, The University of Adelaide, Adelaide 5005, South Australia, Australia.
P A Drew1] Solid Cancer Regulation Research Group, Discipline of Surgery, Basil Hetzel Institute for Translational Health Research, The University of Adelaide, The Queen Elizabeth Hospital, 28 Woodville Road, Woodville South 5011, South Australia, Australia [2] School of Nursing and Midwifery, Flinders University, Bedford Park 5042, South Australia, Australia.
Basil Hetzel Institute · AUFlinders University · AUSouth Australia Pathology · AUUniversity of Adelaide · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe examined whether silencing of IGFBP7 was associated with survival in patients with oesophageal adenocarcinoma.

methodsProtein expression of IGFBP7 was determined using immunohistochemistry in a tissue microarray representing tumours from 65 patients with oesophageal adenocarcinoma who had not had neoadjuvant therapy. DNA methylation of the IGFBP7 promoter was determined with the melt curve analysis in cell lines and patient tissues.

resultsExpression of IGFBP7 was observed in the oesophageal adenocarcinoma of 34 out of 65 (52%) patients and was associated with significantly reduced median (11 vs 92 months) and 5-year survival (25% vs 52%). Multivariate analysis identified expression as an independent prognostic indicator for survival (hazard ratio=3.24, 95% confidence interval=1.58-6.67, P-value=0.0014). Hypermethylation of IGFBP7 was associated with silencing of gene expression in cell lines and patient tissues (P-value=0.0225). Methylation was observed in the squamous mucosa of 2 out of 15 (13%) patients with Barrett's oesophagus and 3 out of 17 (18%) with oesophageal adenocarcinoma. Methylation was observed in 14 out of 18 (78%) of biopsies of Barrett's mucosa and 23 out of 34 (68%) patients with oesophageal adenocarcinoma.

conclusionReduced IGFBP7 protein expression was associated with longer survival in patients with oesophageal adenocarcinoma. Methylation of the IGFBP7 promoter was associated with silencing of gene expression and was frequent in Barrett's oesophagus and oesophageal adenocarcinoma.

Indexed as

AdenocarcinomaAgedAged, 80 and overBiopsyCell Line, TumorDNA MethylationEsophageal NeoplasmsFemaleGene Expression Regulation, NeoplasticHumansInsulin-Like Growth Factor Binding ProteinsKaplan-Meier EstimateMaleMiddle AgedPrognosisPromoter Regions, Geneticinsulin-like growth factor binding protein-related protein 1Insulin-Like Growth Factor Binding Proteins

Identifiers

PMID24357797
PMCPMC3915137
OpenAlexW2052742653

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.